ResMed (NYSE:RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Chairman and Chief Executive Officer Mick Farrell said the company has issued guidance for 5% to 7% core constant-currency revenue growth, including an […]